**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 33-year-old man developed febrile neutropenia, pancytopenia, diarrhoea and COVID-19 infection following treatment with paclitaxel, carboplatin, ifosfamide and etoposide for testicular germ cell tumour (TGCT), yolk sac tumour and teratoma.

The man, who was diagnosed with TGCT (in January 2005) with yolk sac tumour and teratoma, had been treated with bleomycin, ifosfamide, etoposide and cisplatin. In December 2019, he started receiving multi-cycle high-dose chemotherapy (HDCT) TI-CE regimen consisting of paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide with autologous stem cell transplantation (ASCT) \[*routes not stated; not all dosages stated*\]. On 11^th^ March 2020, he was hospitalised to receive third cycle of HDCT. On 14^th^ March 2020, he started receiving carboplatin area under the concentration-time curve (AUC) 7 plus etoposide 400 mg/sqm for three days. Thereafter, he underwent ASCT along with administration of levofloxacin and unspecified granulocyte colony stimulating factor. However, six days after the ASCT, he developed febrile neutropenia along with moderate diarrhoea and abdominal pain. The febrile neutropenia and diarrhoea was considered to be secondary to HDCT.

Levofloxacin therapy was interrupted. The man was treated with piperacillin/tazobactam and paracetamol. Thereafter, he was maintained in the fasted state and treated with total parenteral nutrition. On 24^th^ March 2020, based on the clinical and epidemiologic history, he underwent RTPCR test of nasopharyngeal swab which revealed positive result for SARS-CoV-2. Laboratory investigation revealed severe pancytopenia and elevated level of C-reactive protein. Pancytopenia was considered to have developed secondary to HDCT. The chest and abdomen CT did not reveal pneumonia or abdominal complications. He started receiving off-label treatment with oral ritonavir 100mg once daily, oral hydroxychloroquine 200mg twice daily and oral darunavir 800mg once daily. Thereafter, gradual improvement was observed. His fever resolved after four days. Laboratory investigation revealed progressive decrease in C-reactive protein level and resolution of leucopenia. However, after one week, RTPCR test for SARS-CoV-2 was still found to be positive. Ritonavir, darunavir and hydroxychloroquine were discontinued due to resolution of symptoms. On 1^st^ April 2020, the qSARS-CoV-2 IgG/IgM Rapid test revealed an initial development of an immune-specific response against the virus. On 3^rd^ April 2020, he was discharged due to improved clinical condition. On 11^th^ April 2020, his RT-PCR test for SARS-CoV-2 was found to be negative. Therefore, he was declared to be cured. The HDCT treatment was suspected to have contributed in the development of COVID-19 infection.
